Proteon plans Ph III for elastase in kidney disease surgery
This article was originally published in Scrip
Proteon Therapeutics is planning to move its recombinant human elastase into Phase III trials after announcing positive results from a Phase II trial of the product, PRT-201, in chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) in preparation for hemodialysis.
You may also be interested in...
Shares in Proteon Therapeutics lost nearly three-quarters of their value on news that its first Phase III trial for its lead product vonapanitase had failed. Undeterred, however, the company is increasing the size of its second pivotal study on the back of positive data from certain key endpoints.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.